Payment overview · 2025
General Payments
$398.96
21 reported records · 9 companies
Healthcare provider profile · identity verified
Paul Wayne Davis, MD
Allopathic & Osteopathic Physicians|Family Medicine · WHITE HALL, AR · NPI 1386637221
Verified facts
What the public records show
CMS Open Payments records show Paul Wayne Davis, MD received $398.96 in general payments during 2025 across 21 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $108.78 | 27.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.32 | 19.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.22 | 13.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.15 | 12.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.08 | 9.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.50 | 5.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.74 | 4.7% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $15.35 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.82 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.96 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $108.78 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.68 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1030 | 233 |
| Potassium Chloride | Potassium Chloride | 809 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 737 | 129 |
| Gabapentin | Gabapentin | 706 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 696 | 140 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 587 | 99 |
| Omeprazole | Omeprazole | 563 | 138 |
| Furosemide | Furosemide | 554 | 128 |
| Trazodone Hcl | Trazodone Hcl | 544 | 112 |
| Sertraline Hcl | Sertraline Hcl | 543 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 118 |
| Lisinopril | Lisinopril | 530 | 111 |
| Alprazolam | Alprazolam | 433 | 71 |
| Losartan Potassium | Losartan Potassium | 399 | 88 |
| Allopurinol | Allopurinol | 391 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 374 | 79 |
| Tramadol Hcl | Tramadol Hcl | 350 | 70 |
| Metformin Hcl | Metformin Hcl | 335 | 75 |
| Amitriptyline Hcl | Amitriptyline Hcl | 287 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 56 |
| Glimepiride | Glimepiride | 273 | 65 |
| Ibuprofen | Ibuprofen | 270 | 106 |
| Pregabalin | Pregabalin | 270 | 50 |
| Lovastatin | Lovastatin | 265 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 262 | 46 |
| Sucralfate | Sucralfate | 261 | 82 |
| Meloxicam | Meloxicam | 254 | 57 |
| Bupropion Xl | Bupropion Hcl | 247 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 236 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 230 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 60 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 227 | 47 |
| Buspirone Hcl | Buspirone Hcl | 224 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 209 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 45 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 198 | 42 |
| Nabumetone | Nabumetone | 193 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 188 | 38 |
| Montelukast Sodium | Montelukast Sodium | 177 | 29 |
| Ezetimibe | Ezetimibe | 176 | 37 |
| Baclofen | Baclofen | 167 | 29 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 167 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 165 | 34 |
| Celecoxib | Celecoxib | 159 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 153 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 153 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 151 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 36 |
| Promethazine Hcl | Promethazine Hcl | 148 | 45 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 147 | 67 |
| Alendronate Sodium | Alendronate Sodium | 145 | 27 |
| Clonazepam | Clonazepam | 139 | 27 |
| Estradiol | Estradiol | 139 | 24 |
| Lorazepam | Lorazepam | 136 | 24 |
| Donepezil Hcl | Donepezil Hcl | 135 | 27 |
| Fenofibrate | Fenofibrate | 132 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 131 | 32 |
| Ozempic | Semaglutide | 126 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 31 |
| Eliquis | Apixaban | 122 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 20 |
| Bumetanide | Bumetanide | 115 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 109 | 19 |
| Diclofenac Sodium Er | Diclofenac Sodium | 103 | 26 |
| Simvastatin | Simvastatin | 103 | 25 |
| Famotidine | Famotidine | 102 | 23 |
| Temazepam | Temazepam | 101 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 17 |
| Aripiprazole | Aripiprazole | 95 | 13 |
| Carvedilol | Carvedilol | 94 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 26 |
| Prednisone | Prednisone | 92 | 72 |
| Farxiga | Dapagliflozin Propanediol | 91 | 14 |
| Fluconazole | Fluconazole | 91 | 53 |
| Atenolol | Atenolol | 89 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 19 |
| Nifedipine Er | Nifedipine | 87 | 19 |
| Amoxicillin | Amoxicillin | 85 | 69 |
| Cephalexin | Cephalexin | 85 | 74 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 84 | 69 |
| Dicyclomine Hcl | Dicyclomine Hcl | 75 | 20 |
| Acyclovir | Acyclovir | 72 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 17 |
| Finasteride | Finasteride | 69 | 11 |
| Methocarbamol | Methocarbamol | 68 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 11 |
| Divalproex Sodium | Divalproex Sodium | 67 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 22 |
| Spironolactone | Spironolactone | 64 | 13 |
| Azelastine Hcl | Azelastine Hcl | 62 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 57 | 48 |
| Telmisartan | Telmisartan | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 55 | 22 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 53 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 52 | 13 |
| Jardiance | Empagliflozin | 52 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | 11 |
| Propranolol Hcl | Propranolol Hcl | 48 | 11 |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 30 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Klor-Con M20 | Potassium Chloride | 41 | 15 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Primidone | Primidone | 40 | 11 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 35 |
| Azithromycin | Azithromycin | 38 | 36 |
| Mupirocin | Mupirocin | 38 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 38 | suppressed |
| Carisoprodol | Carisoprodol | 37 | 11 |
| Calcitriol | Calcitriol | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Naproxen | Naproxen | 30 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 12 |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Verapamil Sr | Verapamil Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | 13 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Aranelle | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Butrans | Buprenorphine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Singulair | Montelukast Sodium | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.96 · 21 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AURYON LASER SYSTEM 100-120 VAC, CAPLYTA, CAPVAXIVE, GARDASIL 9, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error